Globally, Hepatitis C is the primary causes of acute and chronic hepatitis in end-stage renal disease patients and highly prevalent in haemodialysis patients. In Asia, HCV infection has become a serious public health problem, whereas, in Pakistan, 26.02% haemodialysis patients are infected with HCV infection. The advent of direct-acting antivirals (DAAs) has brought HCV treatment into a revolutionized era. Among the approved DAAs, sofosbuvir is the only one that has a significant renal elimination whereas daclatasvir is not eliminated by the kidneys. The aims of the study were to assess the effectiveness and safety of Sofosbuvir and daclatasvir combination in HCV infected patients on haemodialysis (HD) in the local population as per routine Pakistani practice. Methods: This was an observational, prospective; single-centre study enrolled 30 HCV HD subjects on sofosbuvir daclatasvir regime for 12 weeks. Results: As per results of 27 subjects’, (n= female 12, 44.5% and n = male 15, 55.5 %), 21 subjects were naïve and 7 were treatment experienced group with mean age ± standard deviation 35.5 ± 9.6 years. On SOF/DAC treatment for 12 weeks, the sustained virological response rate was 100% (27 of 27) at 12 weeks. 95% confidence interval, (95 to 100). No patients had a virologic failure during treatment. No patient had treatment discontinuation due to side effects. No any serious adverse events (AEs) were reported, the reported AEs were mainly nausea, headache and fatigue. Conclusions: The regime of full dose Sofosbuvir and Daclatasvir therapy is well tolerated, safe and with a high rate of SVR in both naïve and treatment experienced group of Hemodialysis Pakistani patients with HCV.